Organogenesis Holdings Inc.

NasdaqCM:ORGO Stock Report

Market Cap: US$346.0m

Organogenesis Holdings Past Earnings Performance

Past criteria checks 2/6

Organogenesis Holdings has been growing earnings at an average annual rate of 39.7%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been growing at an average rate of 14% per year. Organogenesis Holdings's return on equity is 2.1%, and it has net margins of 1.3%.

Key information

39.7%

Earnings growth rate

45.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate14.0%
Return on equity2.1%
Net Margin1.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Recent updates

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Jun 10
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis Holdings: What Now

May 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Nov 30
Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Could Be 24% Above Their Intrinsic Value Estimate

Sep 27
Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Could Be 24% Above Their Intrinsic Value Estimate

Revenue & Expenses Breakdown

How Organogenesis Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ORGO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24435626646
31 Dec 23433526644
30 Sep 234491327744
30 Jun 234571028743
31 Mar 234611329042
31 Dec 224511628240
30 Sep 224635927337
30 Jun 224607125936
31 Mar 224628325433
31 Dec 214679424931
30 Sep 214466223629
30 Jun 214336922624
31 Mar 213794320921
31 Dec 203381720320
30 Sep 20306-520317
30 Jun 20270-3720118
31 Mar 20266-4220317
31 Dec 19261-3920015
30 Sep 19250-4619214
30 Jun 19236-4818113
31 Mar 19215-5816811
31 Dec 18193-6515811
30 Sep 18183-6015010
30 Jun 18184-5214710
31 Mar 18187-3214210
31 Dec 17199-91349
31 Dec 16139-17936
31 Dec 1599-24744

Quality Earnings: ORGO has high quality earnings.

Growing Profit Margin: ORGO's current net profit margins (1.3%) are lower than last year (2.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ORGO has become profitable over the past 5 years, growing earnings by 39.7% per year.

Accelerating Growth: ORGO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ORGO had negative earnings growth (-56.9%) over the past year, making it difficult to compare to the Biotechs industry average (-14.4%).


Return on Equity

High ROE: ORGO's Return on Equity (2.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.